Please use this identifier to cite or link to this item:
Title: A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer
Author: Madurga Díez, Sergio
Foguet, C.
Oliveres, H.
Mas i Pujadas, Francesc
Maurel, J.
Cascante i Serratosa, Marta
Keywords: Càncer colorectal
Assaigs clínics
Colorectal cancer
Clinical trials
Issue Date: 1-Sep-2022
Publisher: Oxford University Press
Abstract: Background: In the last years, a great effort has been made to unify different independent colorectal cancer (CRC) molecular classification systems into four consensus molecular subtypes (CMS). The four subtypes are found to be associated with distinct microenvironmental features and clinical outcome, although metabolic singularities are not well established. Metabolic dysregulation has been reported as a hallmark of CMS3, but metabolic heterogeneity among other subtypes has not been investigated. Here, taking into account the increasing evidence on the importance, for determining response to therapies, of the metabolic crosstalk between cancer cells, tumor microenvironment and immune cells, we investigated the metabolic singularities in the four CMS using a genetic immune-metabolic signature (IMMETCOLS). Conclusions: IMMETCOLS signature refines CMS prognosis in CRC patients and potentially allows specific metabolic interventions in CMS subtypes.
Note: Reproducció del document publicat a:
It is part of: Annals of Oncology, 2022, vol. 33, num. 7, p. S691
Related resource:
ISSN: 0923-7534
Appears in Collections:Articles publicats en revistes (Ciència dels Materials i Química Física)

Files in This Item:
File Description SizeFormat 
725180.pdf105.72 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons